DermatologicNewco news: Infinimmune takes another shot at IL-22 with $75M series AInfinimmune Inc. raised $75 million in a series A round, co-led by Regeneron Ventures and Playground Global, to advance its IL-22-targeted IFX-101 and IL-13-targeted IFX-201 into the clinic in 2027 for atopic dermatitis (AD). Founded in 2022, Alameda, Calif.-based Infinimmune is developing antibodies discovered directly from human immune repertoires, then optimizing them for potency, developability and long half-life.